Trial · NCT07030140
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
NCT07030140, Phase 2, Recruiting, Jinbo Yue
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma. Trials, record NCT07030140. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07030140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
- NCT number
- NCT07030140
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 38 participants, estimated
- Lead sponsor
- Jinbo Yue
- Conditions
- Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer
- Interventions
- Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine, Cisplatin or Oxaliplatin
- First posted
- 2025-06-22
- Last updated
- 2026-10-15
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | Up to 36 months | Defined as the time from initiation of treatment to death from any cause. |
| Secondary | R0 Resection Rate | At the time of surgery (approx. 3-6 months from enrollment) | Proportion of patients achieving microscopically margin-negative (R0) resection among those undergoing surgery. |
| Secondary | Pathological Complete Response (pCR) | At the time of surgery | Absence of residual viable tumor cells in resected specimens. |
| Secondary | Progression-Free Survival (PFS) | Up to 24 months | Time from initiation of treatment to disease progression or death from any cause. |
| Secondary | Local Control Rate | 6, 12, 18, and 24 months | Proportion of patients without local tumor progression at irradiated site. |
| Secondary | Treatment-related Adverse Events | From treatment initiation up to 90 days after last dose | Frequency and severity of adverse events graded by CTCAE v5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07030140
GET https://conductscience.org/api/trials/v1/NCT07030140/registered